Biora presents data on BioJet Oral Biotherapeutic Delivery Platform

Biora Therapeutics shared detailed results from its preclinical study titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist delivered through the BioJet Oral Biotherapeutic Delivery Platform in a Porcine Model,” which were presented during the American Diabetes Association 83rd Scientific Sessions, held June 23-26, 2023 in San Diego, California. “In this preclinical study, we assessed the bioavailability of semaglutide when delivered via our BioJet device in a porcine model. Following administration of semaglutide, the average oral bioavailability was 37%, ranging from 19% to 60%. All dosed animals showed detectable drug levels up to ten days after administration,” said Sharat Singh, PhD, Head of Research at Biora Therapeutics. “We then conducted a second study, which also achieved an average bioavailability of 37%, demonstrating the repeatability of the results.” Biora’s preclinical studies included a single dose of a liquid formulation of ~1 mg of semaglutide. Animals were dosed using the BioJet device, which was administered and activated endoscopically, as is typical in a porcine model, and blood sampling was performed from 0 to 240 hours post-dose, with comparison to a control animal with drug administered intravenously. The BioJet platform is designed to use needle-free, liquid jet injection to deliver drug into the small intestine for systemic absorption, with the potential to deliver almost any liquid drug, without requiring reformulation.